Streetbeat News

Analyst Ratings

ZLAB

Zai Lab (NASDAQ:ZLAB) reported Q3 losses of $(0.71) per share, beating the analyst consensus estimate of $(0.95) by 25.26 percent. However, the company's quarterly sales of $69.23 million missed the analyst consensus estimate of $74.85 million by 7.51 percent.

Portfolio Pulse from bharat@benzinga.com

November 07, 2023 | 9:52 pm

ONTF

ON24 reported Q3 2023 earnings of $0.03 per share, a 142.86% increase YoY. The company's quarterly sales were $39.22M, beating the analyst consensus estimate of $38.01M by 3.19%, but representing a 17.56% decrease from the same period last year.

Portfolio Pulse from saritha@benzinga.com

November 07, 2023 | 9:51 pm

CLAR

Clarus Corporation (NASDAQ:CLAR) reported Q3 earnings of $0.16 per share, missing the analyst consensus estimate of $0.28 by 42.86%. This is a 38.46% decrease from the same period last year. The company also reported quarterly sales of $100.08 million, missing the analyst consensus estimate of $101.65 million by 1.55%. This is a 13.52% decrease from the same period last year.

Portfolio Pulse from bharat@benzinga.com

November 07, 2023 | 9:42 pm

DOUG

Douglas Elliman (NYSE:DOUG) reported Q3 losses of $(0.06) per share, beating the analyst consensus estimate of $(0.08) by 25 percent. However, this is a 20 percent decrease over losses from the same period last year. The company's quarterly sales of $251.55 million missed the analyst consensus estimate of $288.19 million by 12.71 percent, marking a 7.72 percent decrease over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 9:30 pm

HRB

H&R Block reported Q1 adjusted losses of $(1.05) per share, beating the analyst consensus estimate of $(1.12) by 6.25%. The company also reported quarterly sales of $183.80 million, surpassing the analyst consensus estimate of $182.06 million by 0.96%. However, this represents a 6.06% decrease in losses and a 2.12% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 9:28 pm

BBIO

Citi has initiated coverage on BridgeBio Pharma Inc (BBIO) with an optimistic outlook, citing the substantial market potential of acoramidis, especially after its recent Phase 3 successes in treating ATTR cardiomyopathy. Citi recommends a Buy/High Risk with a price target of $42. The analysts also anticipate that acoramidis could achieve blockbuster sales levels post its expected launch in H2 2024. Other promising candidates in BBIO's pipeline include infigratinib, encaleret, and BBP-418.

Portfolio Pulse from Vandana Singh

November 07, 2023 | 9:28 pm

MLYS

Mineralys Therapeutics reported Q3 losses of $(0.57) per share, beating the analyst consensus estimate of $(0.76) by 25 percent. This represents a 55.81 percent increase over losses from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 9:24 pm

ENVX

Enovix (NASDAQ:ENVX) reported Q3 2023 earnings with losses of $(0.19) per share, beating the analyst consensus estimate of $(0.23) by 17.39%. This is a 26.67% decrease over losses from the same period last year. The company also reported quarterly sales of $200.00 thousand, beating the analyst consensus estimate of $120.00 thousand by 66.67%. This is a 2.40K% increase over sales from the same period last year.

Portfolio Pulse from totan@benzinga.com

November 07, 2023 | 9:19 pm

SLRN

Acelyrin (NASDAQ:SLRN) reported Q3 losses of $(0.87) per share, missing the analyst consensus estimate of $(0.47) by 85.11 percent.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 9:19 pm

SGHT

Sight Sciences (NASDAQ:SGHT) reported Q3 2023 earnings per share (EPS) of $(0.27), beating the analyst consensus estimate of $(0.32) by 15.62%. This is a 41.3% increase over losses from the same period last year. However, the company's quarterly sales of $20.01 million missed the analyst consensus estimate of $21.59 million by 7.32%, despite a 7.13% increase over sales from the same period last year.

Portfolio Pulse from totan@benzinga.com

November 07, 2023 | 9:18 pm